Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral ...
17m
The Bull Case For CME Group (CME) Could Change Following High-Profile Globex Outage On Expiry Day
CME Group recently experienced technical outages on its Globex platform that halted trading in key metals and natural gas futures and options on a major contract expiry day, forcing the cancellation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results